此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

2016年5月12日 更新者:GlaxoSmithKline

Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines

The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.

研究概览

地位

终止

研究类型

观察性的

注册 (实际的)

28

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Quezon City、菲律宾、1113
        • GSK Investigational Site
      • Sta. Mesa, Manila、菲律宾
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1个月 至 5年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Healthy Filipino infants and children aged 6 weeks of age to 5 years of age who will receive Synflorix™ as a part of routine practice as per the Prescribing Information in Philippines.

描述

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol.
  • Filipino male or female subjects whose age at the first vaccination with Synflorix™ in this PMS should not be less than 6 weeks of age.
  • Filipino male or female subjects who enter the PMS at the second dose should not be less than 10 weeks of age.
  • Filipino male or female subjects who enter the PMS at the third dose should not be less than 14 weeks of age.
  • Filipino male or female subjects who enter the PMS at the booster dose (i.e. if they have received Synflorix™ in the previous dose/s outside the PMS) should not be less than 10 months of age. The time interval between the primary vaccination and booster dose should be at least 6 months. For the booster dose, subjects who received PCV-7/-13 or Synflorix™ in their primary vaccination series will be allowed to take part in the PMS.
  • Written and signed informed consent obtained from the parents/LAR(s) of the child. Where parents/LAR(s) are illiterate, the consent form will be countersigned by a witness.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Acute disease and/or fever at the time of vaccine administration.
  • Fever is defined as temperature ≥ 37.5°C (99.5°F) on axillary, infrared or tympanic setting.
  • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.
  • Hypersensitivity to latex (found in syringe-tip cap and plunger).
  • Any contraindications as stated in the Prescribing Information.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Synflorix Group
Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Occurrence of grade 3 unsolicited adverse events.
大体时间:Within 31 days (Day 0 - Day 30) after each vaccination.
Within 31 days (Day 0 - Day 30) after each vaccination.

次要结果测量

结果测量
大体时间
Occurrence of unsolicited adverse events.
大体时间:During 31 days (Day 0 - Day 30) follow-up period after each vaccination/vaccine dose.
During 31 days (Day 0 - Day 30) follow-up period after each vaccination/vaccine dose.
Occurrence of serious adverse events.
大体时间:From the Dose 1 up to study end.
From the Dose 1 up to study end.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年5月1日

初级完成 (实际的)

2013年7月1日

研究完成 (实际的)

2013年7月1日

研究注册日期

首次提交

2010年1月7日

首先提交符合 QC 标准的

2010年1月7日

首次发布 (估计)

2010年1月11日

研究记录更新

最后更新发布 (估计)

2016年5月16日

上次提交的符合 QC 标准的更新

2016年5月12日

最后验证

2016年5月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 113381

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Synflorix™的临床试验

3
订阅